Kymera Therapeutics unveils first-in-class oral degrader immunology programs

Jan. 5, 2024

Kymera Therapeutics Inc. has unveiled two new first-in-class oral degrader programs for immune-mediated diseases: KT-621, a STAT6 degrader, and KT-294, a TYK2 degrader.

BioWorld Science Dermatologic Gastrointestinal Immune Respiratory

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2026.

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

Detecting the invisible: minimal residual disease at AACR 2026

BioWorld Science

Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...

Illustration of human face that looks abstract and digital

AACR 2026: The age of agentic AI in oncology

BioWorld Science

New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...